128 related articles for article (PubMed ID: 32334988)
1. Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors.
Ruiz-Camps I; Aguilar-Company J
Infect Dis Clin North Am; 2020 Jun; 34(2):257-270. PubMed ID: 32334988
[TBL] [Abstract][Full Text] [Related]
2. [Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI].
Shao Y; Zhong D
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):381-387. PubMed ID: 32429639
[TBL] [Abstract][Full Text] [Related]
3. Companion biomarkers: paving the pathway to personalized treatment for cancer.
Duffy MJ; Crown J
Clin Chem; 2013 Oct; 59(10):1447-56. PubMed ID: 23656699
[TBL] [Abstract][Full Text] [Related]
4. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.
Bajpe PK; Prahallad A; Horlings H; Nagtegaal I; Beijersbergen R; Bernards R
Oncogene; 2015 Jan; 34(4):531-6. PubMed ID: 24469059
[TBL] [Abstract][Full Text] [Related]
5. [BRAF inhibitor and MEK inhibitor].
Uhara H
Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
[No Abstract] [Full Text] [Related]
6. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
[TBL] [Abstract][Full Text] [Related]
7. Precision Management of Advanced Non-Small Cell Lung Cancer.
Yang CY; Yang JC; Yang PC
Annu Rev Med; 2020 Jan; 71():117-136. PubMed ID: 31986082
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience of MEK inhibitors in cancer therapy.
Wang D; Boerner SA; Winkler JD; LoRusso PM
Biochim Biophys Acta; 2007 Aug; 1773(8):1248-55. PubMed ID: 17194493
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
[TBL] [Abstract][Full Text] [Related]
10. Targeting the human kinome for cancer therapy.
Daly RJ
Crit Rev Oncog; 2012; 17(1):vi-vii. PubMed ID: 22471667
[No Abstract] [Full Text] [Related]
11. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
12. ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.
Jaiswal BS; Durinck S; Stawiski EW; Yin J; Wang W; Lin E; Moffat J; Martin SE; Modrusan Z; Seshagiri S
Clin Cancer Res; 2018 Aug; 24(16):4044-4055. PubMed ID: 29760222
[No Abstract] [Full Text] [Related]
13. Molecular Targets Beyond the Big 3.
Reckamp KL
Thorac Surg Clin; 2020 May; 30(2):157-164. PubMed ID: 32327174
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
15. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
16. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F
Thorac Cancer; 2019 Mar; 10(3):551-556. PubMed ID: 30666799
[TBL] [Abstract][Full Text] [Related]
17. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
Phadke MS; Sini P; Smalley KS
Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
[TBL] [Abstract][Full Text] [Related]
18. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
19. The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.
Ako E; Yamashita Y; Ohira M; Yamazaki M; Hori T; Kubo N; Sawada T; Hirakawa K
Oncol Rep; 2007 Apr; 17(4):887-93. PubMed ID: 17342332
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
